MOLINA HEALTHCARE INC
For the period ended Dec 31, 2024. Filed Feb 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 11, 2025
MOH$206.35+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| (In millions) | |||
| Operating activities: | |||
| Net income | $1,179 | $1,091 | $792 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 186 | 171 | 176 |
| Deferred income taxes | 53 | (31) | (66) |
| Share-based compensation | 116 | 115 | 103 |
| Impairment | — | — | 208 |
| Other, net | 8 | 2 | 8 |
| Changes in operating assets and liabilities, net of the effect of acquisitions: | |||
| Receivables | (78) | (778) | (95) |
| Prepaid expenses and other current assets | (57) | (69) | (124) |
| Medical claims and benefits payable | (40) | 580 | 153 |
| Amounts due government agencies | (453) | 196 | (428) |
| Accounts payable, accrued liabilities and other | 115 | 328 | 55 |
| Deferred revenue | (367) | 59 | (11) |
| Income taxes | (18) | (2) | 2 |
| Net cash provided by operating activities | 644 | 1,662 | 773 |
| Investing activities: | |||
| Purchases of investments | (1,132) | (1,433) | (1,913) |
| Proceeds from sales and maturities of investments | 1,111 | 772 | 1,398 |
| Net cash paid in business combinations | (344) | (3) | (134) |
| Purchases of property, equipment and capitalized software | (100) | (84) | (91) |
| Other, net | 1 | 4 | (50) |
| Net cash used in investing activities | (464) | (744) | (790) |
| Financing activities: | |||
| Common stock purchases | (1,000) | — | (400) |
| Proceeds from senior notes offerings, net of issuance costs | 740 | — | — |
| Proceeds from borrowings under credit facility | 300 | — | — |
| Repayment of credit facility | (300) | — | — |
| Common stock withheld to settle employee tax obligations | (57) | (60) | (54) |
| Contingent consideration liabilities settled | — | — | (20) |
| Other, net | (30) | 2 | 33 |
| Net cash used in financing activities | (347) | (58) | (441) |
| Net (decrease) increase in cash and cash equivalents, and restricted cash and cash equivalents | (167) | 860 | (458) |
| Cash and cash equivalents, and restricted cash and cash equivalents at beginning of period | 4,908 | 4,048 | 4,506 |
| Cash and cash equivalents, and restricted cash and cash equivalents at end of period | $4,741 | $4,908 | $4,048 |
(continued)
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| (In millions) | |||
| Supplemental cash flow information: | |||
| Cash paid during the period for: | |||
| Income taxes, net | $379 | $405 | $340 |
| Interest | $121 | $108 | $108 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.